

# ELECTROMED, INC.

## FOR IMMEDIATE RELEASE

### Contact

Kathleen Skarvan  
President and CEO  
[kskarvan@electromed.com](mailto:kskarvan@electromed.com)  
952-758-9299

## ELECTROMED, INC. ANNOUNCES POSTER PRESENTATION AT THE 2017 WORLD BRONCHIECTASIS CONFERENCE

**New Prague, Minnesota – June 29, 2017** – Electromed, Inc. (NYSE MKT: ELMD) today announced that an abstract highlighting the results of a retrospective case review study comparing exacerbation rates before and after high frequency chest wall oscillation (HFCWO) has been accepted for a scientific poster presentation at the World Bronchiectasis Conference, taking place from July 6 – 8, 2017 in Milan, Italy. The World Bronchiectasis Conference is endorsed by the European Respiratory Society (ERS). The abstract presents data showing consistent use of the SmartVest<sup>®</sup> Airway Clearance System significantly reduces bronchiectasis-related exacerbations which results in a substantial decrease in the need for antibiotics to treat chronic respiratory infections.

The presentation details are as follows:

- Title: Incidence of Bronchiectasis Related Exacerbation Rates after Long-Term Treatment with High Frequency Chest Wall Oscillation (HFCWO)
- Date: July 8, 2017 from 08:00 – 09:00
- Location: University of Milan, Cortile 700

Bronchiectasis is an irreversible, chronic lung condition characterized by enlarged and permanently damaged bronchi. The disease is associated with recurrent respiratory infections, chronic inflammation, reduction in pulmonary function, impaired respiratory secretion clearance, increased hospitalizations and antibiotic/steroid use, and increased morbidity and mortality.<sup>1-3</sup>

“The significant reduction in bronchiectasis-related exacerbations demonstrates the considerable potential of HFCWO, which is the therapy delivered by our SmartVest system, in this population,” commented Kathleen Skarvan, President and CEO of Electromed. “These results support previously published evidence that consistently using the SmartVest system can reduce the number of hospitalizations and save significant healthcare costs.”<sup>4,5</sup>

The SmartVest system uses HFCWO, a clinically proven therapy that helps clear the lungs of excess secretions, reducing the risk of respiratory infections and hospitalizations. HFCWO produces an alternating flow of air into a garment that rapidly compresses and releases the chest wall at a variety of selectable frequencies and pressures, resulting in an oscillation in airflow within the airways that act to loosen, thin, and propel mucus toward the major airways where it can be expectorated or suctioned away.

### About Electromed, Inc.

Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest<sup>®</sup> Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota and founded in 1992. Further information about Electromed can be found at [www.smartvest.com](http://www.smartvest.com).

### References

- [1] King PT *et al.* *COPD*. 2005;2(1):27-34.
- [2] Alzeer AH *et al.* *BMC Pulm Med*. 2007;7:17.
- [3] Seitz AE *et al.* *Chest*. 2010;138(4):944-949.
- [4] Sievert CE *et al.* *Respiratory Therapy Journal*. 2016;11(4): 34–38.
- [5] Sievert CE *et al.* *Respiratory Therapy Journal*. 2017;12(1): 45–49.

###